Rasburicase was administered at a fixed dose of 3 mg to treat 287 episodes of elevated serum uric acid levels (47 mg/dL) in 247 adult patients with hematological malignancies. The median total dose of 36 lg/kg (range: 18-65) was a fraction of the recommended total pediatric dose of 0.75-1.0 mg/kg. The median change in uric acid levels at 24 h was À4.1 mg/dL (range: À12 to þ 1) and À45% (range: À95 to þ 9). Uric acid levels normalized at 24 h in 72% of patients. There was no relationship between the weight-based dose and uric acid decline. The only predictor of success was the baseline uric acid; the failure rate was 84% with baseline level 412 mg/dL and 18% if it was p12. Uric acid levels continued to decline beyond 24 h in most patients without additional treatment. Serum creatinine remained stable over 24 h, and declined over 48 h and 7 days. There was no relationship between the extent of reduction in uric acid levels and serum creatinine. We conclude that a single 3-mg dose of rasburicase, used with close monitoring, is sufficient to treat most adults with uric acid levels up to 12 mg/dL.
Introduction
Hyperuricemia, resulting from rapid cell turnover and breakdown of DNA byproducts, is frequently seen in patients with aggressive hematological malignancies, especially when the tumor burden is high and when cytotoxic therapy is started. Hyperuricemia can result in kidney impairment and, when part of tumor lysis syndrome (TLS), significant morbidity and mortality. 1 Conventional management comprising hydration, urine alkalinization and the administration of allopurinol is not always adequate to prevent renal complications of hyperuricemia. Allopurinol affects purine metabolism by inhibiting xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine, and of xanthine to uric acid. 2 Allopurinol lowers serum uric acid levels by inhibiting uric acid formation and has no direct effect on existing uric acid levels in the blood.
Urate oxidase is a peroxisomal enzyme catalyzing the oxidation of uric acid to allantoin. This enzyme is present in most mammals except humans and certain other primates. 3 Murine urate oxidase has been used successfully to treat hyperuricemia. It reduces uric acid levels rapidly by converting uric acid to allantoin, which is 5-10 times more soluble than uric acid and is readily excreted in the urine. Expression of the gene encoding urate oxidase in yeast yields recombinant enzyme in therapeutically useful quantities. 4 Recombinant urate oxidase (rasburicase) has been found to be useful in managing hyperuricemia. [5] [6] [7] [8] The recommended pediatric dose of rasburicase (0.15-0.20 mg/kg for 3-7 days) is very effective for adults as well. Indeed, it usually lowers the serum uric acid concentration to levels much below the normal range. 9 It is unclear whether such drastic reduction in uric acid level has any therapeutic benefit on renal function. The cost of using the standard dose of rasburicase in adults is very high, 10 resulting in widespread institutional restrictions on its use. Unfortunately, such curbs can result in delay or deprivation of therapy with this highly effective drug in appropriate circumstances.
The use of lower doses of rasburicase provides an alternate approach to lowering uric acid level. Our original report 10 and other publications 11, 12 have shown that a single dose of rasburicase that is much lower than the recommended pediatric dose, with frequent monitoring of uric acid levels and additional doses as needed, lowers uric acid levels successfully into the normal range in adults. Early and late treatment failures-either inadequate lowering of the uric acid level or an increase after an initial decline-requiring additional doses of rasburicase are seen in a proportion of patients. [10] [11] [12] Although risk factors for the development of hyperuricemia and TLS have been identified, 13 factors associated with the outcome of single low-dose rasburicase therapy are unknown. Additionally, data on the use of rasburicase in hematopoietic SCT (HSCT) recipients are limited. 10 We have retrospectively evaluated the effectiveness of an initial 3-mg rasburicase dose in 287 episodes of hyperuricemia associated with hematological malignancies and factors associated with treatment outcome.
Patients and methods
All patients with hematological malignancies who received an initial 3-mg dose of rasburicase for hyperuricemia between June 2003 and January 2008 at Northwestern Memorial Hospital were identified from the pharmacy database. Laboratory results and clinical information were retrieved from the hospital's information system (electronic records). The patients selected for analysis had to meet the following criteria: a baseline uric acid level of over 7 mg/dL (the upper limit of normal in our institution), and 24-h post-rasburicase serum uric acid and creatinine levels available. Patients who did not have this basic laboratory information available were excluded. None of the patients died within 24 h of rasburicase administration (that is, no exclusions because of early death). Patients could have received one or more additional rasburicase doses (any dose and at any interval; usually administered at the discretion of the managing physician) as long as the first dose was 3 mg.
Supportive therapy included hydration, urinary alkalinization, diuretics, and allopurinol depending on the clinical status. Blood samples were preserved on ice by personnel handling the specimens to avoid falsely low uric acid levels that may occur because of ongoing uric acid degradation in the blood taken for analysis. When creatinine or uric acid level was measured more than once close to the time of interest (for example. 24 or 48 h after therapy), the highest value was used in the analysis. Treatment failure was defined as a post-therapy uric acid level 47 mg/dL or 45 mg/dL at 24 (24/7 and 24/ 5) or 48 (48/7 and 48/5) h after the initial rasburicase dose was administered. Clinical TLS was defined based on published criteria. 14 If a patient received 3 mg rasburicase on more than one occasion, each occasion was enumerated and analyzed separately as long as the episodes were clinically distinct (interval between the two doses at least 7 days; usually several weeks; median 48 days). Any repeat administration of rasburicase within 7 days of the initial dose was considered to be part of the same episode of therapy. Patients receiving rasburicase during conditioning for HSCT or within 7 days of transplantation were considered to be in the HSCT group (122 treatment episodes), and the rest were considered to be in the non-HSCT group (165 treatment episodes).
Continuous variables were compared using the Wilcoxon rank-sum test and categorical variables using the Fisher's exact test. Multivariate linear regression analysis was used to assess correlation between different variables (baseline uric acid level, dose in mg/kg, age, diagnosis, HSCT vs no HSCT, age, sex, renal function) and outcomes. This retrospective review was approved by the Institutional Review Board as part of studies investigating the outcomes of transplant recipients and patients being treated for hematological malignancies. Table 1 shows the characteristics of 287 treatment episodes in 247 patients. This includes 40 of the 43 treatment episodes described previously; 10 three were excluded because the baseline uric acid level was o7 mg/dL. More than half the treatment episodes (n ¼ 146; 130 autologous, 16 allogeneic) were in HSCT recipients, 122 within the first week after HSCT (included in the HSCT group). As expected, there were differences in the HSCT and non-HSCT populations reflecting the fact that the former usually started therapy under more controlled circumstances.
Results
A single dose of rasburicase was administered in 236 instances. Among 51 episodes treated with 41 dose of rasburicase, the number of additional doses was 1 (n ¼ 42; 5 HSCT, 37 non-HSCT), 2 (n ¼ 5; 1 HSCT, 4 non-HSCT) or 3 (n ¼ 4; all non-HSCT).
As Table 2 shows, a single dose was effective in restoring uric acid to normal levels (p7 mg/dL) 24 h later in 72% of patients, and in lowering uric acid level substantially (p5 mg/dL) in 48%. Figure 1 illustrates the highly significant correlation between the baseline and 24-h uric acid levels-and explains that the response differences seen in the HSCT and non-HSCT groups in Table 2 are related to the different baseline values in the groups.
There was no correlation between the weight-adjusted dose (mg/kg) and the absolute (r ¼ 0.08; P ¼ 0.18) or per cent (r ¼ 0.07, P ¼ 0.26) change in uric acid in the first 24 h, indicating no obvious dose-response relationship. Although a single dose of rasburicase lowered the uric acid level by at least 10% in 93% of patients as shown in Table 2 , there was a broad range of responses with considerable inter-patient variability as seen in Figure 2 .
Among the 224 patients who received only one dose of rasburicase and had a 48-h uric acid level available, 48/7 failure was seen in only 7 (3%) and 48/5 failure in 44 (20%). This indicates that the uric acid level keeps declining beyond 24 h despite not giving an additional dose of the drug. This is shown in Figure 3a . Figure 3b shows that only in 2 of 224 patients did the serum uric acid level spike back to higher than the baseline level. It increased above the 24-h level in o10% of patients.
The baseline uric acid levels for patients not experiencing 24/7 failure (7.1-16.9 mg/dL) were significantly lower (Po0.0001) than the levels in those experiencing 24/7 failure (8.1-27.3 mg/dL). This was also true for 24/5 failure: 7.1-16 mg/dL compared with 7.2-27.3 mg/dL (Po0.0001). Table 3 shows that higher baseline uric acid levels were more likely to be associated with failure. Figure 4 shows the median uric acid levels among patients who experienced 24/7 or 24/5 failures by whether they received an additional drug or not. The trajectory of the solid lines shows clearly that the additional drug dose(s) accelerated the tempo of uric acid decline.
In keeping with the lack of a marked change in serum creatinine level in half of the patients (Table 2) , the correlation between the baseline and 24-h creatinine levels was very high (r ¼ 0.95; Po0.0001). The median 48-h serum creatinine level was stable at 1.6 mg/dL (n ¼ 282). The median 1-week serum creatinine level was lower at Figure 5 shows that there was no obvious relationship between the uric acid level at 24 h and the per cent change in serum creatinine levels from baseline to 24 h. There was one documented case of methemoglobinemia, a known adverse effect of rasburicase. The baseline serum uric acid level was the only factor that was independently and significantly associated with 24/7 and 24/5 failures in multivariate regression analysis.
Discussion
Our data demonstrate the effectiveness of a single low dose of rasburicase in lowering serum uric acid levels in patients with hematological malignancies, including those undergoing HSCT. Although retrospective, this represents the largest single-center report of rasburicase therapy. Moderately elevated uric acid levels were successfully lowered into the normal range in the majority of patients after a single 3-mg dose of rasburicase. Renal function remained stable early after therapy and improved over the subsequent week. Baseline uric acid level was the only factor predicting treatment success, and the likelihood of lowering uric acid levels into the normal range declined with increasing baseline uric acid levels. As the median change in serum uric acid level 24 h after a single 3-mg dose was 4.1 mg/dL, uric acid did not consistently normalize when the baseline levels were higher than 10-12 mg/dL. seen in TLS are known to affect renal function, and could have complicated the interpretation of our results. The major strength of the study is that the drug was administered under the complex conditions that are normally seen in clinical practice, often in elderly patients with existing or impending renal dysfunction and other comorbidities.
Dosing guidelines for rasburicase in adults do not exist because the drug currently has no approved indication in adults. When given at the approved pediatric dose, it is extremely effective in lowering uric acid levels in adults to virtually undetectable levels. The utility of lowering uric acid levels to such an extent is unclear. As Figure 5 shows, change in serum creatinine was independent of the 24-h uric acid level. If a decline in serum creatinine was closely correlated with low uric acid level, the four lines would not overlap, and the line representing the lowest-quartile uric acid values would be clearly better (in this case lower on the graph) than the highest quartile.
Additionally, there is a misconception, perhaps inadvertently engendered by some of the publications on rasburicase, that the drug prevents TLS. This is obviously incorrect. Hyperuricemia is one of the several features of TLS. Successful management of this complex, life-threatening condition requires multiple interventions-one of which is rasburicase.
The cost of using pediatric doses in adults is prohibitive: the price of the drug (Redbook) increased from $340 per . Because of cost concerns, the use of rasburicase is severely restricted at most institutions. This has the potential of depriving patients of an extremely effective intervention to lower uric acid levels under appropriate circumstances. In our opinion, the strategy described in this paper strikes the right balance between cost and benefit. At the doses used, our total cost was lesser than $400 000 based on the 2009 price.
The lack of correlation between rasburicase dose based on body weight (a wide range, including obese patients) and the extent response is difficult to explain and may in part be due to the fact that rasburicase is a biological agent rather than a drug. Previous reports have not addressed this issue.
However, it is also clear that the 3-mg dose is inadequate for a substantial proportion of patients with baseline uric acid levels that are higher than 10-12 mg/dL. Based on our data, definitive recommendations cannot be made on the management of such patients. However, we suggest the following options for future trials or clinical practice (we use both). These should be used in conjunction with other measures such as hydration, frequent clinical and laboratory monitoring, electrolyte restoration, hemodialysis, and management of the underlying malignancy.
Option 1: A 3-mg dose for all patients with hyperuricemia irrespective of the extent of uric acid elevation. Uric acid levels to be checked every 6 h-with administration of additional 3-mg doses if levels still elevated. This option results in some patients receiving more doses of drug than necessary because the uric acid level continues to decline beyond 24 h after just a single dose. However, the approach is relatively simple.
Option 2: A 3-mg dose for all patients with a baseline serum uric acid level that is p12 mg/dL, and a 6-mg dose Table 3 Failure of therapy at 24 h in relation to baseline uric acid level for patients with uric acid levels that are higher. Uric acid levels to be repeated every 6 h. No repeat dose to be given in the lower baseline group unless the level is rising, and a repeat 3-mg dose to be given at 24 h if the level is still elevated. Additional 3 mg doses to be given to patients with the higher baseline uric acid levels whenever the repeat level is high. Although more complex, this algorithm minimizes unnecessary use of the drug. We conclude that a single 3-mg dose of rasburicase lowers moderately elevated serum uric acid levels into the normal range in the majority of adult patients. Frequent monitoring and repeat doses as needed are crucial for optimal treatment. The baseline uric acid level is the best predictor of treatment success. A prospective clinical study of a fixed low dose of rasburicase with additional doses as warranted based on uric acid levels vs multiple low doses at fixed intervals would be interesting.
Note added during revision (February 2010): Rasburicase has now been approved by the US Food and Drug Administration for use in adults at the dose of 0.2 mg/kg per day for up to 5 days.
